(Q38787954)

6 September 2017

title

A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy (English)

1 reference

6 September 2017

7

Ramesh Akkina

1 reference

6 September 2017

Shuang Hu

1

1 reference

6 September 2017

Charles Preston Neff

2

1 reference

6 September 2017

Dipu Mohan Kumar

3

1 reference

6 September 2017

Yuichiro Habu

4

1 reference

6 September 2017

Sarah R Akkina

5

1 reference

6 September 2017

Takahiro Seki

6

1 reference

6 September 2017

language of work or name

English

0 references

publication date

29 November 2016

1 reference

6 September 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

6 September 2017

volume

501

1 reference

6 September 2017

page(s)

115-118

1 reference

New generation humanized mice for virus research: comparative aspects and future prospects

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

HIV-1 antiretroviral drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Update on human immunodeficiency virus (HIV)-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

HIV-2: the forgotten AIDS virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Antiretroviral therapy response among HIV-2 infected patients: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Slower heterosexual spread of HIV-2 than HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Dose translation from animal to human studies revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Human immunodeficiency virus type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

Dolutegravir for the treatment of HIV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.11.013

10.1016/J.VIROL.2016.11.013

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference